KPTI Valuation

Karyopharm Therapeutics Inc

Add to Watchlist

Advanced Chart

4.430

-0.43(-8.848%)1D

Overview
Forecast
Valuation
Earnings

KPTI Relative Valuation

KPTI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KPTI is overvalued; if below, it's undervalued.

Historical Valuation

Karyopharm Therapeutics Inc (KPTI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.22 is considered Undervalued compared with the five-year average of -2.68. The fair price of Karyopharm Therapeutics Inc (KPTI) is between 393.09 to 480.84 according to relative valuation methord. Compared to the current price of 4.43 USD , Karyopharm Therapeutics Inc is Undervalued By 98.87%.

Relative Value

Fair Zone

393.09-480.84

Current Price：4.43

98.87%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-0.20

P/B

Median3y

-3.51

Median5y

-2.24

-365.05

FCF Yield

Median3y

-103.64

Median5y

-71.11

Competitors Valuation Multiple

The average P/S ratio for KPTI's competitors is 84.39, providing a benchmark for relative valuation. Karyopharm Therapeutics Inc Corp (KPTI) exhibits a P/S ratio of 0.22, which is -99.74% above the industry average. Given its robust revenue growth of -9.39%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

KPTI.O

Karyopharm Therapeutics Inc

0.22

Average P/S: 84.39

-9.39%